Review of tipranavir in the treatment of drug-resistant HIV

References

• BackNKvan WijkARemmerswaalDIn vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitorsAids200014101210714580
   PubMed Web of Science ®Google Scholar
• BartlettJADeMasiRQuinnJOverview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adultsAids20011513697711504958
   PubMed Web of Science ®Google Scholar
• BodenDHurleyAZhangLHIV-1 drug resistance in newly infected individualsJAMA199928211354110501116
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim.2004. Unpublished data. Boehringer Ingelheim GmbH Investigator’s Brochure
   Google Scholar
• Boehringer Ingelheim GmbH InternationalAptivus (tipranavir) Capsules -SPC2005
   Google Scholar
• Boehringer Ingelheim GmbH InternationalProduct Monograph, Aptivus (tipranavir)2005
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals IncAptivus (tipranavir) Capsules -Prescribing Information2005
   Google Scholar
• BoffitoMMaitlandDPozniakAPractical perspectives on the use of tipranavir in combinations with other medications: Lessons learned from pharmacokinetic studiesJ Clin Pharmacol200646130916432264
   PubMed Web of Science ®Google Scholar
• CahnPHicksCTeamsf.t.R.-a.R.-S. 2005. RESIST-1 (R-1) and RESIST-2 (R-2) 48 week meta-analyses demonstrate superiority of protease inhibitor (PI) tipranavir+ritonavir (TPV/r) over an optimized comparator PI (CPI/r) regimen in antiretroviral (ARV) experienced patients10th European AIDS Conference (EACS)17–20 November 2005Dublin, Ireland Abs. # PS3/8
   Google Scholar
• CarpenterCCCooperDAFischlMAAntiretroviral therapy in adults: Updated recommendations of the international AIDS society-U S A PanelJAMA20002833819010647802
   PubMed Web of Science ®Google Scholar
• ChenRYWestfallAOMugaveroMJDuration of highly active antiretroviral therapy regimensClin Infect Dis2003377142212942406
   PubMed Web of Science ®Google Scholar
• ClavelFHanceAJHIV drug resistanceN Engl J Med200435010233514999114
   PubMed Web of Science ®Google Scholar
• ClotetBRaffiFCooperDClinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendationsAids20041811374615166529
   PubMed Web of Science ®Google Scholar
• CooperDHicksCCahnP24-week RESIST study analyses: The efficacy of tipranavir/ritonavir is superior to lopinavir/ritonavir, and the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen2005Conference on Retroviral and Opportunistic Infections (CROI)2005Boston, MA Abs # 560
   Google Scholar
• DoyonLTremblaySBourgonLSelection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavirAntiviral Res200568273516122817
   PubMed Web of Science ®Google Scholar
• GatheJKohlbrennerVMPieroneGTipranavir/ritonavir demonstrates potent efficacy in multiple protease inhibitor experienced patients: BI 1182.52200310th Conference on Retroviral an Opportunistic Infections (CROI)Boston Abs. # 179
   Google Scholar
• GmbHBIInvestigator’s Brochure2004
   Google Scholar
• GongYFRobinsonBSRoseREIn vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632Antimicrob Agents Chemother20004423192610952574
   PubMed Web of Science ®Google Scholar
• HicksCRESIST-1: A phase 3, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in antiretroviral (ARV) experienced patients: 24-week trial200444th Interscience Conference on Antimicrobial Agents and ChemotherapyOctober 30 – November 2Washington, DC; 2004 Abstract H-1137a
   Google Scholar
• HicksCCahnCPCooperDAfor the RESIST Investigator GroupDurable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trialsLancet20063684667516890833
   PubMed Web of Science ®Google Scholar
• JacobsenHYasargilKWinslowDLCharacterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959Virology1995206527347831807
   PubMed Web of Science ®Google Scholar
• JohnsonVABrun-VezinetFClotetBUpdate of the drug resistance mutations in HIV-1: 2005Top HIV Med20051351715849371
   PubMedGoogle Scholar
• JonesJLHansonDLDworkinMSSurveillance for AIDS-defining opportunistic illnesses, 1992–1997MMWR CDC Surveill Summ19994812212412613
   PubMedGoogle Scholar
• KatlamaCBergerDBellosNEfficacy of TMC114/r in 3-class experienced patients with limited treatment options: 24-week planned interim analysis of 2 96-week multinational dose-finding Trials2005Conference on Retroviral and Opportunistic Infections (CROI)2005Boston, MA 164LB
   Google Scholar
• KempSDSalimMFieldNSite-directed mutagenesis and in vitro drug selection studies have failed to reveal a consistent genotypic resistance pattern for tipranavirInterscience Conference on Antimicrobial Agents and Chemotherapy2000 Abstract # 2113
   Google Scholar
• KingNMPrabu-JeyabalanMNalivaikaEAStructural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitorJ Virol200478120122115479840
   PubMed Web of Science ®Google Scholar
• KohYNakataHMaedaKNovel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitroAntimicrob Agents Chemother2003473123914506019
   PubMed Web of Science ®Google Scholar
• LampeFGatellJStaszewskiSTrends over time in initial virological failure of first HAART: 1996 to 20022005A joint cohort Analysis of 4143 subjects conference on retroviral and opportunistic infections (CROI)2005Boston, MA Abstr. # 593
   Google Scholar
• LarderBAHertogsKBloorSTipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samplesAids2000141943810997398
   PubMed Web of Science ®Google Scholar
• LeithJWalmsleySKatlamaCPharmacokinetics and safety of Tipranavir/Ritonavir (TPV/r) Alone or in Combination with Saquinavir (SQV), Amprenavir (APV), or Lopinavir (LPV): Interim analysis of BI1182.515th International Workshop on Clinical Pharmacology of HIV Therapy, Rome, Italy2004 session 5 Abs. 5.1
   Google Scholar
• LittleSJHolteSRoutyJPAntiretroviral-drug resistance among patients recently infected with HIVN Engl J Med20023473859412167680
   PubMed Web of Science ®Google Scholar
• MarkowitzMMoHKempfDJSelection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitorJ Virol19956970167815532
   PubMed Web of Science ®Google Scholar
• MarkowitzMMohriHMehandruSInfection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case reportLancet20053651031815781098
   PubMed Web of Science ®Google Scholar
• McCallisterSValdezHCurryKA 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patientsJ Acquir Immune Defic Syndr2004353768215097154
   PubMed Web of Science ®Google Scholar
• MontanerJSChallenges of the unmet needs in the treatment-experienced patientAIDS Read200313S5912838741
   PubMedGoogle Scholar
• PalellaFJJrDelaneyKMMoormanACDeclining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study InvestigatorsN Engl J Med1998338853609516219
   PubMed Web of Science ®Google Scholar
• PieroneGDrulakMArastehKA long-term open-label rollover trial assessing the safety and tolerability of combination tipranavir and ritonavir (TPV/r) Use in HIV-1–infected patients2005The 3rd IAS Conference on HIV Pathogenesis and Treatment (IAS 2005)July 24–27, 2005Rio de Janeiro, Brazil Poster WePe6.2C05
   Google Scholar
• PolisMASidorovIAYoderCCorrelation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacyLancet20013581760511734232
   PubMed Web of Science ®Google Scholar
• PoppeSMSladeDEChongKTAntiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitorAntimicrob Agents Chemother1997411058639145869
   PubMed Web of Science ®Google Scholar
• RichmanDDMortonSCWrinTThe prevalence of antiretroviral drug resistance in the United StatesAids2004181393140115199315
   PubMed Web of Science ®Google Scholar
• RockstrohJSulkowskiMNeubacherD24-Week Efficacy of tipranavir boosted with ritonavir (TPV/r) in Hepatitis B (HBV) or Hepatitis C (HCV) Co-Infected Patients200545th Annual Interscience Conference on Antimicrobial Agents and ChemotherapyDecember 16–19th, 2005Washington D.C. H-525
   Google Scholar
• RockstrohJVillacianJQuinsonA24-week analysis of the efficacy of tipranavir boosted with ritonavir (TPV/r) in HIV patients stratified by previous protease inhibitor (PI) Use200510th European AIDS Conference (EACS)November 17–20, 2005Dublin, Ireland PE7.9/11
   Google Scholar
• RusconiSLa Seta CatamancioSCitterioPSusceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitorsAntimicrob Agents Chemother20004413283210770770
   PubMed Web of Science ®Google Scholar
• SchwartzRKazanjianPSlaterLResistance to tipranavir is uncommon in a randomized trial of tipranavir/ritonavir (TPV/RTV) in Multiple PI-Failure Patients (BI 1182.2)20029th Conference on Retroviruses and Opportunistic Infections2002Seattle, WA Session 75, Poster Session 562-T
   Google Scholar
• ThaisrivongsSStrohbachJWStructure-based discovery of Tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitorBiopolymers19995151810380352
   PubMed Web of Science ®Google Scholar
• Van HeeswijkRSaboJCooperCThe pharmacokinetic interaction between tipranavir/ritonavir 500/200 mg bid (TPV/r) and atorvastatin, antacid, and CYP3A4 in healthy adult volunteers5th International Workshop on Clinical Pharmacology of HIV Therapy, Rome, Italy2004 Abstract #35
   Google Scholar
• van LethFPhanuphakPRuxrungthamKComparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN StudyLancet200436312536315094269
   PubMed Web of Science ®Google Scholar
• WilkinTHaubrichRSteinhartCTMC114/r Superior to Standard of Care in 3-Class-Experienced Patients: 24-Wks Primary Analysis of the Power 2 Study (C202)200545th Annual Interscience Conference on Antimicrobial Agents and ChemotherapyDecember 16–19th, 2005Washington D.C. H-413
   Google Scholar
• WuAHuangILoboFHealth-related quality of life with tipranavir in combination with an optimized background regimen in 2 randomized clinical trials200512th Conference on Retroviruses and Opportunistic InfectionsFebruary 22–25, 2005Boston, Massachusetts Poster #654
   Google Scholar
• YeniPGHammerSMHirschMSTreatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA PanelJAMA20042922516515249575
   PubMed Web of Science ®Google Scholar